Here is what patients need to know about compounded versus brand-name GLP-1 medication: the real difference is not the molecule but who checked what actually ended up in the vial. Branded semaglutide and tirzepatide, sold as Wegovy, Ozempic, Zepbound and Mounjaro, go through FDA review of their exact formulation, concentration and manufacturing process before a single dose reaches a patient. Compounded versions do not. That single difference is why we prescribe branded GLP-1 medication exclusively, and never compounded semaglutide or tirzepatide, under any circumstance.
TL;DR
- Compounded GLP-1s are not FDA-approved; branded ones (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) are.
- The national shortages that gave compounding pharmacies legal room to mass-produce semaglutide and tirzepatide copies were declared resolved in 2025 and late 2024, narrowing the legal basis sharply.
- FDA adverse event reports tied to compounded GLP-1s in 2023-2024 centered on dosing errors, unverified salt forms, and unapproved additives, not the drug mechanism itself.
- We prescribe branded, FDA-approved GLP-1 medication only, billed by the pharmacy at pharmacy cost, with zero markup. Our $299/month fee covers the physician relationship and a Biomarker Audit every 90 days, and never changes with your dose.
- GoodLife Health prescribes branded GLP-1 medication exclusively and never compounded semaglutide or tirzepatide.
- The shortage designations that once allowed mass compounding of these drugs are over: tirzepatide resolved December 2024, semaglutide resolved February 2025.
- The clinical concern with compounded versions is verification, not the molecule's effectiveness.
- Membership is a flat $299/month after an initial $598 charge, and covers the physician relationship plus a Biomarker Audit every 90 days, not the medication.
- Medication is billed separately, directly by the pharmacy, at pharmacy cost, with no markup as doses increase.
What "compounded" actually means
A compounding pharmacy mixes a custom version of a drug, often because a patient needs a dose strength, allergen-free formulation, or delivery form that no manufactured product offers. That is a legitimate, longstanding pharmacy practice for the right clinical situation. What happened with semaglutide and tirzepatide from 2022 through 2024 was different: 503A and 503B compounding pharmacies used the FDA's shortage designation on both drugs to mass-produce copies at scale, marketed broadly as a cheaper alternative to Wegovy, Ozempic, Zepbound and Mounjaro, not as a response to an individual patient's unmet clinical need.
That shortage-driven legal window has closed. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024. Once a shortage ends, the broad legal basis for mass compounding narrows to a much smaller clinical exception, and most of what was sold as routine compounded GLP-1 therapy in the preceding two years does not fit it.
The actual safety gap
The molecule itself, semaglutide or tirzepatide, is well studied. STEP 1 (Wilding et al., NEJM 2021) showed a 14.9% mean body weight reduction on branded semaglutide at 68 weeks. SURMOUNT-1 showed up to approximately 22.5% mean reduction on the highest tirzepatide dose at 72 weeks. Individual results vary, and both trials paired medication with lifestyle intervention.
The gap is not efficacy, it is verification. FDA approval means a specific formulation, made in a specific facility, under specific manufacturing controls, was tested for identity, potency and sterility before release, and every subsequent batch is held to that standard. Compounded GLP-1s skip that check. The FDA's adverse event database logged hundreds of reports in 2023 and 2024 tied to compounded semaglutide and tirzepatide, concentrated in three patterns: dosing errors from patients drawing imprecise volumes out of concentrated, pharmacy-mixed vials; semaglutide salt forms (acetate, sodium) marketed as equivalent to the active ingredient in Wegovy and Ozempic despite no published human safety data, which the FDA specifically warned against in 2024; and tirzepatide preparations with unapproved additives like B12, sold as enhancements with no trial data behind them.
Compounded vs. Branded GLP-1 Medication
| Factor | Compounded semaglutide/tirzepatide | Branded (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) |
|---|---|---|
| FDA review of the finished product | None | Full approval, audited manufacturing |
| Active ingredient confirmed | Depends on the individual compounder | Manufacturer-guaranteed |
| Dosing method | Often a concentrated vial, patient draws the dose | Pre-measured pen or tablet |
| Legal basis in 2026 | Narrow exception only, post-shortage | Standard prescribing pathway |
| Who prescribes it at GoodLife Health | Never | Exclusively |
Why we never make an exception
We get asked whether we will prescribe compounded semaglutide or tirzepatide for a patient who cannot afford the branded version, or who has used a compounded protocol successfully before. The answer is no, and it is not a pricing decision dressed up as a safety one. We built our entire model specifically to remove the reason patients reach for compounded product in the first place: price.
Our membership is a flat $299 per month, after a $598 charge that covers your first two months, including intake and your first Biomarker Audit. That fee covers your physician relationship and a comprehensive Biomarker Audit every 90 days, run through the Beluga Health lab network: ApoB, Lp(a), hs-CRP, HbA1c, full hormone and thyroid panels. It does not cover medication. The medication, Wegovy, Ozempic, Zepbound, Mounjaro or oral Foundayo, is billed to you separately, directly by the pharmacy, at pharmacy cost. No molecule upcharge. No dose-escalation fee. As your dose climbs, the pharmacy's cost for more drug climbs with it, but our fee for the doctor does not move. We make money when you get healthier, not when your dose gets stronger. That structure is what makes branded, FDA-approved medication accessible without a markup, not a private-label compounded copy.
What this looks like clinically
Weight, blood sugar, lipids, inflammation and hormones move together in the body, which is why GLP-1 therapy is not a standalone intervention in our model. Your Biomarker Audit at baseline and again at 90 days tracks how your whole metabolic system is responding, not just the number on the scale. If HbA1c or inflammatory markers shift in a direction that needs attention, a physician sees it in the data before it becomes a symptom you notice on your own.
Your Biomarker Audit at baseline and again at 90 days tracks how your whole metabolic system is responding, not just the number on the scale. If HbA1c or inflammatory markers shift in a direction that needs attention, a physician sees it in the data before it becomes a symptom you notice on your own.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. That ongoing relationship, reviewing real lab data every quarter, is the actual safeguard in GLP-1 therapy. The source of the vial is not something a patient should have to verify alone.
FAQ
What is the real difference between compounded and brand-name GLP-1 medication?
Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) went through FDA review of their exact formulation, manufacturing process and dosing before approval. Compounded versions are made by individual pharmacies without that independent review, so there is no guaranteed verification of what is actually in the vial.
Is compounded semaglutide or tirzepatide still legal in 2026?
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That removed the broad legal basis compounding pharmacies used to mass-produce copies, leaving only a narrow exception for documented, patient-specific clinical needs.
Why doesn't GoodLife Health ever prescribe compounded GLP-1 medication?
We prescribe branded, FDA-approved GLP-1 medication exclusively, billed by the pharmacy at pharmacy cost with zero markup. Our membership is structured specifically so price is never the reason a patient would consider an unregulated, compounded alternative.
Are compounded GLP-1s less effective than branded ones?
The concern is not whether the molecule works, it is whether the compounded product reliably contains what it claims at the concentration it claims. No independent agency verifies that before it reaches a patient, which is the core difference from an FDA-approved product.
How much does branded GLP-1 therapy cost through GoodLife Health?
Membership is a flat $299 per month after a $598 charge covering the first two months. That fee covers your physician relationship and a Biomarker Audit every 90 days. Medication is billed separately, directly by the pharmacy, at pharmacy cost.
What were the main safety issues reported with compounded GLP-1s?
FDA adverse event reports from 2023 and 2024 centered on dosing errors from concentrated vials, unverified semaglutide salt forms with no published safety data, and tirzepatide preparations with unapproved additives.
Can I switch from a compounded GLP-1 to a branded one?
Yes. It is a routine clinical conversation based on your current dose and how you have responded. A physician can start an equivalent branded dose and continue titration from there.
One last thing
The choice between compounded and branded GLP-1 therapy is really a choice about who is accountable for what is in the syringe and who is watching what it does to your body.
The choice between compounded and branded GLP-1 therapy is really a choice about who is accountable for what is in the syringe and who is watching what it does to your body. We built our model so that choice is never a financial trade-off. One flat fee for the doctor. Zero markup on the medicine. Learn more about medical weight loss inside Cardiometabolic Optimization, or see how direct primary care structures the relationship behind it.
Related Guides
- Why we moved away from compounded semaglutide
- Why we moved away from compounded tirzepatide
- GLP-1 side effects: what to expect in the first month
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/